Literature DB >> 9851751

The use of radioactive iodine in patients with papillary and follicular thyroid cancer.

L Wartofsky1, S I Sherman, J Gopal, M Schlumberger, I D Hay.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9851751     DOI： 10.1210/jcem.83.12.5293-1

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  29 in total

Review 1.  The management of metastatic differentiated thyroid carcinoma.

Authors:  S I Sherman
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat?

Authors:  C Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07       Impact factor: 9.236

3.  Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.

Authors:  A S Alzahrani; G Mohamed; A Al Shammary; S Aldasouqi; S Abdal Salam; M Shoukri
Journal:  J Endocrinol Invest       Date:  2005-06       Impact factor: 4.256

4.  Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer.

Authors:  Hussam M Binyousef; Ali S Alzahrani; Saif S Al-Sobhi; Suhaibani Hamed S Al; Mohammed A Chaudhari; Hussain M Raef
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

Review 5.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

6.  Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer.

Authors:  V Oliynyk; O Epshtein; T Sovenko; M Tronko; R Elisei; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

7.  Short-term outcome of differentiated thyroid cancer patients receiving a second iodine-131 therapy on the basis of a detectable serum thyroglobulin level after initial treatment.

Authors:  Leonardo Pace; Michele Klain; Carmine Albanese; Barbara Salvatore; Giovanni Storto; Andrea Soricelli; Marco Salvatore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-05       Impact factor: 9.236

8.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

9.  Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.

Authors:  A S Alzahrani; H Raef; A Sultan; S Al Sobhi; S Ingemansson; M Ahmed; A Al Mahfouz
Journal:  J Endocrinol Invest       Date:  2002-06       Impact factor: 4.256

10.  Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer.

Authors:  Bernadette Biondi; Melania Pulcrano; Loredana Pagano; Gaetano Lombardi
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.